A Practical Approach and Framework to Quality Management for Psychedelic Drug Development
Psychedelic Medicine January 7, 2026 Peer reviewed DOI: 10.1177/28314425251409550
Summary
Quality management systems must be integrated into clinical studies from the start, particularly for psychedelic drug development. The International Council for Harmonization guidelines emphasize identifying critical quality factors during protocol development to assess risks to participants and data integrity. This applies equally to smaller companies in the field. Despite challenges like controlled substance scheduling, adherence to regulations is crucial for ensuring participant safety and reliable data.
Study at a glance
| Key finding | Establishing a robust quality management system is essential for ensuring participant safety and data reliability in clinical trials, especially in the context of psychedelic drug development. |
|---|
Abstract
Sponsor companies and physician investigators engaged in clinical research, including those involved in psychedelic drug development, are to design quality into the clinical studies upfront as outlined in International Council for Harmonization (ICH) E8 R1, General Considerations for Clinical Studies, and ICH E6 R3, Guideline for Good Clinical Practice. Identification of what is critical to quality should be done at the time of protocol development, facilitating the assessment of risks to participants and data integrity. Sponsors should develop systems to manage quality throughout all stages of the trial process, per ICH E6, and ensure that quality oversight is commensurate with the risks associated in clinical development programs to support informed decision-making. Quality system elements should be designed to facilitate compliance, be flexible enough to accommodate shifting priorities, and mature with the growth of the company. For smaller start-up companies involved in psychedelic drug development programs, the same requirements apply as they would for the research and development of any other drug, biological, or device product. While there are challenges in developing a psychedelic for potential market approval due to controlled substance scheduling and the inclusion of psychological assistance or psychotherapy components, adherence to regulations is required to ensure participant safety and data reliability, which can be achieved through the establishment and maintenance of a robust quality management system.